
Answering the Lack of Diversity in Clinical Trials
Identifying and implementing ways to increase diversity in clinical trials is a growing topic in the industry. Almost 40 percent of Americans belong to a racial or ethnic minority, but roughly 80-90 percent of participants in clinical trials for new drugs are still disproportionately Caucasian.1
In order to make sure drugs and treatments are safe and reliable to all people, there needs to be a better representation of minorities in clinical trials.
Read More